Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Think Your Patent Case is Exceptional?


October 3, 2013

In a lawsuit for patent infringement, "[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party."1 Patent litigation often is costly and an award of attorney fees can substantially affect the court’s final judgment. As a result, both plaintiffs and defendants often request that the court deem a case "exceptional" and award attorney fees.

Notwithstanding the regularity with which parties request an "exceptional case" finding, patent litigants often are disappointed or even disillusioned with the "exceptional case" analysis. For starters, it is unusual for a district court to find a case "exceptional," even when it enters judgment of infringement or non-infringement as a matter of law. When the district court takes the rare step of finding a case "exceptional," the Federal Circuit often disagrees with the district court’s analysis, its conclusion, or both. Perhaps the most popular criticism of the "exceptional case" rule is that it does not sufficiently dissuade patent "trolls" from bringing unmeritorious suits in an attempt to extract a nuisance settlement.

The United States Supreme Court now has an opportunity to address these perceived shortcomings. Under existing Federal Circuit law, a case is "exceptional" if the losing party’s positions were (1) objectively baseless, and (2) asserted in subjective bad faith.2 This week, the United States Supreme Court agreed to hear two cases to address the application of this two-part test.

In the first case, Highmark, Inc. v. Allcare Health Management Systems, Inc.,3 the district court entered a final judgment of non-infringement and found the case exceptional because patent claims were asserted frivolously and the patentee engaged in litigation misconduct. A panel of the Federal Circuit agreed that one patent claim was asserted frivolously, but it found that the district court’s other bases did not support an exceptional case finding.4 Accordingly, it remanded the case for the district court to calculate attorneys’ fees based on the single frivolous asserted claim. The Federal Circuit then issued a deeply divided decision denying rehearing en banc to determine whether the panel should have given deference to the district court’s determination of objective baselessness.5 This week, the Supreme Court agreed to consider that question.6

In the second case, Icon Health & Fitness, Inc. v. Octane Fitness, LLC,7 the district court entered summary judgment of non-infringement, but declined to find the case exceptional. A panel of the Federal Circuit affirmed the judgment of non-infringement and only briefly addressed the exceptional case issues. The accused infringer argued that the patentee took unreasonable claim construction positions, improperly attempted to claim privilege in pre-suit investigation documents, and brought the litigation in bad faith. The panel declined the accused infringer’s request to lower the standard to "objectively unreasonable" without a showing of bad faith "to rebalance what it alleges as the power of large companies in patent infringement litigation." The Federal Circuit panel succinctly stated that "[w]e have no reason to revisit the settled standard for exceptionality." This week, however, the Supreme Court granted the accused infringer’s petition for certiorari to determine whether the "rigid and exclusive two-part test" for exceptionality contravenes statutory intent.8

Interestingly, both of these cases raise the "exceptional case" question from the defense side. That is, when a defendant is awarded judgment of non-infringement, in what circumstances should it also be awarded its attorneys' fees? In recent months, policymakers have shown increased interest in the effect that patent "trolls" are having on patent litigation, innovation, and, ultimately, the national economy.9 The Supreme Court’s decisions on the "exceptional case" standard may be influenced by these policy and public opinion issues surrounding "trolls."

Any change to the "exceptional case" test could substantially alter the litigation playing field and settlement dynamic in future cases, and we will provide an update when the Supreme Court issues its opinions next year.

If you have any questions about the content of this alert, please contact one of the authors listed above or any member of our Intellectual Property and Technology team.

1 35 U.S.C. § 285 (2013).
2 See Highmark v. Allcare Health Mgmt. Sys., Inc., 687 F.3d 1300, 1308 (Fed. Cir. Aug. 7, 2012).
3 Highmark v. Allcare Health Mgmt. Sys., Inc., 701 F.3d 1351 (Fed. Cir. Dec. 6, 2012).
4 Highmark v. Allcare Health Mgmt. Sys., Inc., 687 F.3d 1300 (Fed. Cir. Aug. 7, 2012).
5 Highmark v. Allcare Health Mgmt. Sys., Inc., 701 F.3d 1351 (Fed. Cir. Dec. 6, 2012).
6 Highmark v. Allcare Health Mgmt. Sys., Inc., 2013 U.S. LEXIS 5130 (Oct. 1, 2013).
7 Icon Health & Fitness, Inc. v. Octane Fitness, LLC, 496 F. App’x 57 (Fed. Cir. Oct. 24, 2012).
8 Octane Fitness, LLC v. Icon Health & Fitness, Inc., 2013 U.S. LEXIS 5133 (Oct. 1, 2013).
9 See, e.g., FACT SHEET: White House Task Force on High-Tech Patent Issues (June 4, 2013); Executive Office of the President, Patent Assertion and U.S. Innovation (June 2013); U.S. Government Accountability Office, Report to Congressional Committees, Intellectual Property: Assessing the Factors that Affect Patent Infringement Litigation Could Help Improve Patent Quality (Aug. 2013).

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.